4.8 Review

Tuberculosis

Journal

LANCET
Volume 387, Issue 10024, Pages 1211-1226

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(15)00151-8

Keywords

-

Funding

  1. Foundation of Innovative New Diagnostics (FIND)
  2. eNose Company
  3. Statens Serum Institut
  4. bioMeriux
  5. ALERE
  6. Oxford Immunotec
  7. Qiagen
  8. Cepheid
  9. Antrum Biotec
  10. Hain Lifescience
  11. Hain Life science
  12. YD Daignostics
  13. FIND

Ask authors/readers for more resources

Although the worldwide incidence of tuberculosis has been slowly decreasing, the global disease burden remains substantial (similar to 9 million cases and similar to 1.5 million deaths in 2013), and tuberculosis incidence and drug resistance are rising in some parts of the world such as Africa. The modest gains achieved thus far are threatened by high prevalence of HIV, persisting global poverty, and emergence of highly drug-resistant forms of tuberculosis. Tuberculosis is also a major problem in health-care workers in both low-burden and high-burden settings. Although the ideal preventive agent, an effective vaccine, is still some time away, several new diagnostic technologies have emerged, and two new tuberculosis drugs have been licensed after almost 50 years of no tuberculosis drugs being registered. Efforts towards an effective vaccine have been thwarted by poor understanding of what constitutes protective immunity. Although new interventions and investment in control programmes will enable control, eradication will only be possible through substantial reductions in poverty and overcrowding, political will and stability, and containing co-drivers of tuberculosis, such as HIV, smoking, and diabetes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available